CLINICAL_TRIALS
trial_result
· 2024-06-10
Clinical Trial Update: Bioequivalence Study of Pimavanserin 34 mg Capsule [Phase 1]
Summary
This update reports the completion of a Phase 1 bioequivalence study of pimavanserin 34 mg capsules for Parkinson disease psychosis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Humanis Saglık Anonim Sirketi | Conditions: Parkinson Disease Psychosis | Phase 1 | Status: COMPLETED